Phase II trial of docetaxel and liposomal doxorubicin (Doxil) chemotherapy combined with enoxaparin in patients with advanced pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 31 Dec 2017
At a glance
- Drugs Docetaxel (Primary) ; Doxorubicin liposomal (Primary) ; Enoxaparin sodium (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Apr 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Apr 2009 Planned end date (Jan 2009) added as reported by ClinicalTrials.gov.